Relmada Therapeutics (RLMD) Misses Q4 EPS by 1c

Relmada Therapeutics (NASDAQ: RLMD) reported Q4 EPS of ($0.84), $0.01 worse than the analyst estimate of ($0.83).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Gaxos.ai Inc. (GXAI) Reports Q2 EPS of $0.02
• Logistic Properties of the Americas (LPA) Reports Q2 results